What Happened?
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.
The prior day’s rally was triggered after Moderna and its partner Merck announced that their personalized mRNA cancer vaccine for melanoma succeeded in a late-stage trial, according to a joint company press release. The subsequent can be attributed to profit-taking.
The selling got another push from Wall Street. TipRanks reported that several analysts raised their ratings, but their new price targets still sat below where the stock last closed, which reads less like a green light to keep buying and more like a warning that the rally may have gotten ahead of itself. The companies also didn’t put out hard numbers on how well the vaccine performed, which likely kept some investors from getting too excited.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. But moves this big are rare even for Moderna and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was about 24 hours ago when the stock gained 144% on the news that its personalized mRNA cancer vaccine, developed with Merck, met key goals in a late-stage trial.
The company noted in a press release that the treatment, Intismeran, reduced the risk of melanoma recurrence and prevented tumors from spreading when combined with Merck’s Keytruda, compared with Keytruda alone. In addition, the readout marked the first successful late-stage trial for an mRNA cancer vaccine, validating Moderna’s platform beyond COVID-19. JPMorgan analysts told Reuters the vaccine’s launch is crucial to Moderna’s return to profitability.
Moderna is up 328% since the beginning of the year, but at $132.17 per share, it is still trading 24.2% below its 52-week high of $174.38 from August 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at only $345.07.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Source link
